Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ulodesine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP known ✓ | P00491 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ulodesine SCHEMBL13606448 | 1.00 | PNP (1.00) | PNP | |
| Ulodesine SCHEMBL12715509 | 1.00 | PNP (1.00) | PNP | |
| Ulodesine SCHEMBL4736609 | 1.00 | PNP (1.00) | PNP | |
| Ulodesine SCHEMBL29548630 | 0.93 | PNP (0.86) | PNP | |
| SCHEMBL15315689 | 0.90 | PNP (0.81) | PNP | |
| SCHEMBL9888172 | 0.90 | PNP (0.81) | PNP | |
| SCHEMBL13713299 | 0.89 | PNP (0.80) | PNP | |
| SCHEMBL15318135 | 0.88 | PNP (0.78) | PNP | |
| SCHEMBL13178208 | 0.88 | PNP (0.78) | PNP | |
| SCHEMBL9888126 | 0.88 | PNP (0.78) | PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731204-A2 | SELECTIVE RBP4 ANTAGONIST AND C20-D3-RETINOL FOR TREATING MACULAR DEGENERATION, NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), AND GOUTY ARTHRITIS (GOUT) | The Trustees Of Columbia University In The City Of New York (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260000663-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-01-01 | — | — | US | claimed |
| WO-2025264823-A1 | TREATMENT OF DISEASE | METASHAPE PHARMA AG (CH) | 2025-12-26 | — | — | WO | claimed |
| EP-4633636-A1 | PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF METABOLIC SYNDROME AND ASSOCIATED CONDITIONS | Metashape Pharma AG (CH) | 2025-10-22 | — | — | EP | claimed |
| US-12440486-B2 | RBP4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-10-14 | — | — | US | claimed |
| US-20250127787-A1 | METHODS FOR TREATING PERIPHERAL NEUROPATHY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-04-24 | — | — | US | claimed |
| US-20250099496-A1 | Dihydronicotinamide Riboside (NRH) Therapy for Osteoarthritis and other Conditions | UNIVERSITY OF SOUTH ALABAMA | 2025-03-27 | — | — | US | claimed |
| WO-2024263790-A2 | NOVEL CO-DRUG, CO-ADMINISTRATION, AND SEQUENTIAL ADMINISTRATION OF SELECTIVE RBP4 ANTAGONIST AND C20-D3-RETINOL FOR ELIMINATION OF MECHANISM-BASED OCULAR ADVERSE EFFECTS IN TREATING MACULAR DEGENERATION, NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), AND GOUTY ARTHRITIS (GOUT) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-12-26 | — | — | WO | claimed |
| EP-4408531-A1 | METHODS FOR TREATING PERIPHERAL NEUROPATHY | University of Pittsburgh - of the Commonwealth System of Higher Education (US) | 2024-08-07 | — | — | EP | claimed |
| WO-2024126630-A1 | PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF METABOLIC SYNDROME AND ASSOCIATED CONDITIONS | METASHAPE PHARMA AG (CH) | 2024-06-20 | — | — | WO | claimed |
| US-20230241049-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-03 | — | — | US | claimed |
| WO-2023141188-A1 | DIHYDRONICOTINAMIDE RIBOSIDE (NRH) THERAPY FOR OSTEOARTHRITIS AND OTHER CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-27 | — | — | WO | claimed |
| CN-112430221-B | Compound for preventing, treating or relieving hyperuricemia or gout and application thereof | 成都诺和晟泰生物科技有限公司 | 2023-06-23 | — | — | CN | claimed |
| WO-2023055531-A1 | METHODS FOR TREATING PERIPHERAL NEUROPATHY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-04-06 | — | — | WO | claimed |
| US-20230089949-A1 | SMALL MOLECULES FOR TREATING AGE-RELATED RETINAL DISEASES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-03-23 | — | — | US | claimed |
| EP-4138820-A1 | SMALL MOLECULES FOR TREATING AGE-RELATED RETINAL DISEASES | University of Pittsburgh - of the Commonwealth System of Higher Education (US) | 2023-03-01 | — | — | EP | claimed |
| US-20220211710-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH NUCLEOSIDE-METABOLISM MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-07-07 | — | — | US | claimed |
| US-20220054494-A1 | METHODS FOR TREATING BLADDER AND URETHRA DYSFUNCTION AND DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-02-24 | — | — | US | claimed |
| WO-2021216461-A1 | SMALL MOLECULES FOR TREATING AGE-RELATED RETINAL DISEASES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-10-28 | — | — | WO | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4731204-A2 | SELECTIVE RBP4 ANTAGONIST AND C20-D3-RETINOL FOR TREATING MACULAR DEGENERATION, NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), AND GOUTY ARTHRITIS (GOUT) | The Trustees Of Columbia University In The City Of New York (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| US-20260000663-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2025264823-A1 | TREATMENT OF DISEASE | METASHAPE PHARMA AG (CH) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025264823-A1 | TREATMENT OF DISEASE | METASHAPE PHARMA AG (CH) | 2025-12-26 | — | — | WO | disclosed |
| US-20250345206-A1 | APPARATUS AND METHODS FOR OCULAR INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4633636-A1 | PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF METABOLIC SYNDROME AND ASSOCIATED CONDITIONS | Metashape Pharma AG (CH) | 2025-10-22 | — | — | EP | disclosed |
| US-12440486-B2 | RBP4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-10-14 | — | — | US | disclosed |
| US-12350261-B2 | Methods and devices for the treatment of ocular diseases in human subjects | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250186253-A1 | DEVICES AND METHODS FOR ADJUSTING THE INSERTION DEPTH OF A NEEDLE FOR MEDICAMENT DELIVERY | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4566672-A2 | METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS | Clearside Biomedical Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-3554435-B1 | SYSTEMS FOR DELIVERING DRUGS TO RETINAL TISSUE | CLEARSIDE BIOMEDICAL INC (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250152413-A1 | SYSTEMS, DEVICES, AND METHODS FOR NEEDLE-LESS OCULAR INJECTIONS | CLEARSIDE BIOMEDICAL INC (US) | 2025-05-15 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20250127787-A1 | METHODS FOR TREATING PERIPHERAL NEUROPATHY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-04-24 | — | — | US | disclosed |
| US-20250099496-A1 | Dihydronicotinamide Riboside (NRH) Therapy for Osteoarthritis and other Conditions | UNIVERSITY OF SOUTH ALABAMA | 2025-03-27 | — | — | US | disclosed |
| EP-3721872-B1 | METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS | CLEARSIDE BIOMEDICAL INC (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12201558-B2 | Apparatus and methods for ocular injection | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| WO-2024263790-A2 | NOVEL CO-DRUG, CO-ADMINISTRATION, AND SEQUENTIAL ADMINISTRATION OF SELECTIVE RBP4 ANTAGONIST AND C20-D3-RETINOL FOR ELIMINATION OF MECHANISM-BASED OCULAR ADVERSE EFFECTS IN TREATING MACULAR DEGENERATION, NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), AND GOUTY ARTHRITIS (GOUT) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-12-26 | — | — | WO | disclosed |
| CN-119014473-A | Dietary nutritional supplement with uric acid reducing effect based on green brick tea water extract and application thereof | 上海交通大学 | 2024-11-26 | — | — | CN | disclosed |
| US-12127975-B2 | Devices and methods for adjusting the insertion depth of a needle for medicament delivery | CLEARSIDE BIOMEDICAL, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| EP-3496680-B1 | DEVICE FOR ADJUSTING THE INSERTION DEPTH OF A NEEDLE FOR MEDICAMENT DELIVERY | CLEARSIDE BIOMEDICAL INC (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-4408531-A1 | METHODS FOR TREATING PERIPHERAL NEUROPATHY | University of Pittsburgh - of the Commonwealth System of Higher Education (US) | 2024-08-07 | — | — | EP | disclosed |
| WO-2024126630-A1 | PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF METABOLIC SYNDROME AND ASSOCIATED CONDITIONS | METASHAPE PHARMA AG (CH) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024126630-A1 | PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF METABOLIC SYNDROME AND ASSOCIATED CONDITIONS | METASHAPE PHARMA AG (CH) | 2024-06-20 | — | — | WO | disclosed |
| US-12006329-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| EP-4378444-A2 | APPARATUS AND METHODS FOR OCULAR INJECTION | Clearside Biomedical, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| EP-4373579-A1 | ULODESINE SALT | Laevoroc Immunology AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-118021983-A | Preparation method and application of intelligent environmental response type treatment system for hyperuricemia and gout | 宁波慈溪生物医学工程研究所 | 2024-05-14 | — | — | CN | disclosed |
| CN-117897383-A | Wu Luo Di Xin salt | 莱沃罗克免疫学股份公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117897383-A | Wu Luo Di Xin salt | 莱沃罗克免疫学股份公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-114127078-B | Heterocompounds and methods of use thereof | 重庆复创医药研究有限公司 | 2024-03-01 | — | — | CN | disclosed |
| EP-3417896-B1 | APPARATUS AND METHODS FOR OCULAR INJECTION | CLEARSIDE BIOMEDICAL INC (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2024015652-A1 | SYSTEMS, DEVICES, AND METHODS FOR NEEDLE-LESS OCULAR INJECTIONS | CLEARSIDE BIOMEDICAL, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-4306524-A2 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | PureTech LYT, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-20230363941-A1 | APPARATUS AND METHODS OF RETINAL INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| WO-2023187599-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | DIDENKO KIRILL (MX) | 2023-10-05 | — | — | WO | disclosed |
| EP-3413851-B1 | PACKAGING | CLEARSIDE BIOMEDICAL INC (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230265153-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD (GB) | 2023-08-24 | — | — | US | disclosed |
| EP-4225235-A1 | APPARATUS AND METHODS OF RETINAL INJECTION | Clearside Biomedical, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230241049-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-03 | — | — | US | disclosed |
| WO-2023141188-A1 | DIHYDRONICOTINAMIDE RIBOSIDE (NRH) THERAPY FOR OSTEOARTHRITIS AND OTHER CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-27 | — | — | WO | disclosed |
| CN-112430221-B | Compound for preventing, treating or relieving hyperuricemia or gout and application thereof | 成都诺和晟泰生物科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230157869-A1 | APPARATUS AND METHODS FOR OCULAR INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11623932-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| WO-2023055531-A1 | METHODS FOR TREATING PERIPHERAL NEUROPATHY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023001893-A4 | ULODESINE SALT | LAEVOROC IMMUNOLOGY AG (CH) | 2023-03-30 | — | — | WO | disclosed |
| US-20230089949-A1 | SMALL MOLECULES FOR TREATING AGE-RELATED RETINAL DISEASES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230083551-A1 | Formulations for the Suprachoroidal Space of an Eye and Methods | EMORY UNIVERSITY | 2023-03-16 | — | — | US | disclosed |
| US-11596545-B2 | Systems and methods for ocular drug delivery | CLEARSIDE BIOMEDICAL, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20230065814-A1 | CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2023-03-02 | — | — | US | disclosed |
| EP-4138820-A1 | SMALL MOLECULES FOR TREATING AGE-RELATED RETINAL DISEASES | University of Pittsburgh - of the Commonwealth System of Higher Education (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2023001893-A1 | ULODESINE SALT | LAEVOROC IMMUNOLOGY AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| US-11559428-B2 | Apparatus and methods for ocular injection | CLEARSIDE BIOMEDICAL, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| US-20230011269-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A POTENT INHIBITOR OF URAT1 | ASTRAZENECA AB (SE) | 2023-01-12 | — | — | US | disclosed |
| US-11548928-B2 | Engineered platelets for targeted delivery of a therapeutic agent | JPV01 LTD. (GB) | 2023-01-10 | — | — | US | disclosed |
| US-11518796-B2 | Engineered platelets for targeted delivery of a therapeutic agent | JPV01 LTD. (GB) | 2022-12-06 | — | — | US | disclosed |
| EP-2887982-B1 | APPARATUS FOR DRUG DELIVERY USING MICRONEEDLES | CLEARSIDE BIOMEDICAL INC (US) | 2022-11-23 | — | — | EP | disclosed |
| US-11504431-B2 | Formulations for the suprachoroidal space of an eye and methods | EMORY UNIVERSITY (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220354860-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | FOCHON PHARMACEUTICALS, LTD. (CN) | 2022-11-10 | — | — | US | disclosed |
| US-20220305129-A1 | CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2022-09-29 | — | — | US | disclosed |
| US-20220280341-A1 | APPARATUS AND METHODS FOR DRUG DELIVERY USING MICRONEEDLES | CLEARSIDE ROYALTY LLC | 2022-09-08 | — | — | US | disclosed |
| US-20220280386-A1 | METHODS AND APPARATUS FOR EXTRACTING FLUID FROM CONTAINER | CLEARSIDE BIOMEDICAL, INC. | 2022-09-08 | — | — | US | disclosed |
| US-20220251165-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-08-11 | — | — | US | disclosed |
| EP-4026898-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-07-13 | — | — | EP | disclosed |
| US-20220211710-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH NUCLEOSIDE-METABOLISM MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-07-07 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-3986477-A1 | CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986472-A1 | CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| EP-3983415-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | Fochon Pharmaceuticals, Ltd. (CN) | 2022-04-20 | — | — | EP | disclosed |
| WO-2022076938-A1 | APPARATUS AND METHODS OF RETINAL INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-109641898-B | 5, 7-dihydro-pyrrolo-pyridine derivatives for the treatment of neurological and neurodegenerative diseases | 辉瑞公司 | 2022-04-08 | — | — | CN | disclosed |
| EP-3177294-B1 | COMPOSITIONS COMPRISING A PNP INHIBITOR FOR USE IN THE TREATMENT OF THE RELAPSE OF MALIGNANCY FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANT | LAEVOROC IMMUNOLOGY AG (CH) | 2022-03-23 | — | — | EP | disclosed |
| EP-3177294-B1 | COMPOSITIONS COMPRISING A PNP INHIBITOR FOR USE IN THE TREATMENT OF THE RELAPSE OF MALIGNANCY FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANT | LAEVOROC IMMUNOLOGY AG (CH) | 2022-03-23 | — | — | EP | disclosed |
| CN-114127078-A | Hybrid compounds and methods of use thereof | 重庆复创医药研究有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20220054494-A1 | METHODS FOR TREATING BLADDER AND URETHRA DYSFUNCTION AND DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| EP-3397627-B1 | INDOLIZINE DERIVATIVES, COMPOSITION AND METHODS OF USE | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2022-01-26 | — | — | EP | disclosed |
| WO-2021216461-A1 | SMALL MOLECULES FOR TREATING AGE-RELATED RETINAL DISEASES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-10-28 | — | — | WO | disclosed |
| WO-2020186187-A1 | METHODS FOR TREATING BLADDER AND URETHRA DYSFUNCTION AND DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-09-17 | — | — | WO | disclosed |
| US-10137112-B2 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | CYMABAY THERAPEUTICS, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| EP-2775836-B1 | METHODS FOR TREATING GOUT FLARES | CYMABAY THERAPEUTICS INC (US) | 2018-09-12 | — | — | EP | disclosed |
| US-20180214420-A1 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | CYMABAY THERAPEUTICS, INC. (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180161314-A1 | Methods for Treating Hyperuricemia and Related Diseases | ARDEA BIOSCIENCES, INC. | 2018-06-14 | — | — | US | disclosed |
| US-20180161314-A1 | Methods for Treating Hyperuricemia and Related Diseases | ARDEA BIOSCIENCES, INC. | 2018-06-14 | — | — | US | disclosed |
| US-20180055803-A1 | Methods for Treating Gout Flares | CYMABAY THERAPEUTICS, INC. (US) | 2018-03-01 | — | — | US | disclosed |
| US-9801860-B2 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | CYMABAY THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170209447-A1 | Use of PNP Inhibitor to Treat Relapse of Malignancy after Hematopoietic Stem Cell Transplant | NITOR THERAPEUTICS | 2017-07-27 | — | — | US | disclosed |
| US-9616129-B2 | Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency | NITOR THERAPEUTICS (US) | 2017-04-11 | — | — | US | disclosed |
| US-9452217-B2 | Methods for potentiating immune response for the treatment of infectious diseases and cancer | NITOR THERAPEUTICS (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160271111-A1 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | CYMABAY THERAPEUTICS, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-9439891-B2 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | CYMABAY THERAPEUTICS, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9433612-B2 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | CYMABAY THERAPEUTICS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160051520-A1 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | CYMABAY THERAPEUTICS, INC. (US) | 2016-02-25 | — | — | US | disclosed |
| WO-2016022166-A1 | USE OF PNP INHIBITOR TO TREAT RELAPSE OF MALIGNANCY AFTER HEMATOPOIETIC STEM CELL TRANSPLANT | NITOR THERAPEUTICS (US) | 2016-02-11 | — | — | WO | disclosed |
| US-20150258053-A1 | Methods for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halofenic Acid and a Second Urate-Lowering Agent | CYMABAY THERAPEUTICS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-9060987-B2 | Methods for treating gout flares | CYMABAY THERAPEUTICS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| CN-102448963-B | Useful pharmaceutical salts of 7- [ (3R,4R) -3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl ] -3, 5-dihydro-pyrrolo [3,2-d ] pyrimidin-4-one | BIOCRYST PHARM INC | 2015-06-17 | — | — | CN | disclosed |
| US-9023856-B2 | Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent | CYMABAY THERAPEUTICS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| EP-2836209-A1 | METHOD FOR TREATING HYPERURICEMIA IN PATIENTS WITH GOUT USING HALOFENATE OR HALOFENIC ACID AND AN ANTI-INFLAMMATORY AGENT | Cymabay Therapeutics, Inc. (US) | 2015-02-18 | — | — | EP | disclosed |
| US-20140378482-A1 | Compositions and methods for potentiating immune response for the treatment of infectious diseases and cancer | NITOR THERAPEUTICS (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140377250-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE RESPONSE, ENHANCING IMMUNOTHERAPY, AND INCREASING VACCINE POTENCY | NITOR THERAPEUTICS (US) | 2014-12-25 | — | — | US | disclosed |
| WO-2014205194-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE RESPONSE FOR THE TREATMENT OF INFECTIOUS DISEASES AND CANCER | NITOR THERAPEUTICS (US) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014205199-A2 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE RESPONSE, ENHANCING IMMUNOTHERAPY, AND INCREASING VACCINE POTENCY | NITOR THERAPEUTICS (US) | 2014-12-24 | — | — | WO | disclosed |
| EP-2773336-A1 | METHODS FOR TREATING HYPERURICEMIA IN PATIENTS WITH GOUT USING HALOFENATE OR HALOFENIC ACID AND A SECOND URATE-LOWERING AGENT | METABOLEX, INC. (US) | 2014-09-10 | — | — | EP | disclosed |
| EP-2411394-B1 | USEFUL PHARMACEUTICAL SALTS OF 7-[(3R, 4R)-3-HYDROXY-4-HYDROXYMETHYL-PYRROLIDIN-1-YLMETHYL]-3,5-DIHYDRO-PYRROLO[3,2-D]PYRIMIDIN-4-ONE | BIOCRYST PHARM INC (US) | 2014-08-06 | — | — | EP | disclosed |
| EP-2411394-B1 | USEFUL PHARMACEUTICAL SALTS OF 7-[(3R, 4R)-3-HYDROXY-4-HYDROXYMETHYL-PYRROLIDIN-1-YLMETHYL]-3,5-DIHYDRO-PYRROLO[3,2-D]PYRIMIDIN-4-ONE | BIOCRYST PHARM INC (US) | 2014-08-06 | — | — | EP | disclosed |
| EP-2411394-B1 | USEFUL PHARMACEUTICAL SALTS OF 7-[(3R, 4R)-3-HYDROXY-4-HYDROXYMETHYL-PYRROLIDIN-1-YLMETHYL]-3,5-DIHYDRO-PYRROLO[3,2-D]PYRIMIDIN-4-ONE | BIOCRYST PHARM INC (US) | 2014-08-06 | — | — | EP | disclosed |
| US-20140128438-A1 | Methods for Treating Gout Flares | METABOLEX, INC. | 2014-05-08 | — | — | US | disclosed |
| US-20140128439-A1 | Methods for Treating Gout Flares | METABOLEX, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20130302305-A1 | Methods for Treating Gout in Patients Subpopulations | METABOLEX, INC. | 2013-11-14 | — | — | US | disclosed |
| US-20130296345-A1 | METHODS FOR TREATING HYPERURICEMIA AND RELATED DISEASES | ARDEA BIOSCIENCES, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130274331-A1 | Method for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halofenic Acid and an Anti-Inflammatory Agent | DIATEX, INC. | 2013-10-17 | — | — | US | disclosed |
| WO-2013155478-A1 | METHOD FOR TREATING HYPERURICEMIA IN PATIENTS WITH GOUT USING HALOFENATE OR HALOFENIC ACID AND AN ANTI-INFLAMMATORY AGENT | METABOLEX, INC. (US) | 2013-10-17 | — | — | WO | disclosed |
| EP-2627331-A1 | METHODS FOR TREATING HYPERURICEMIA AND RELATED DISEASES | Ardea Biosciences, Inc. (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8501753-B2 | Useful pharmaceutical salts of 7-[(3R, 4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3, 5-dihydro-pyrrolo [3, 2-D] pyrimidin-4-one | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501753-B2 | Useful pharmaceutical salts of 7-[(3R, 4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3, 5-dihydro-pyrrolo [3, 2-D] pyrimidin-4-one | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501753-B2 | Useful pharmaceutical salts of 7-[(3R, 4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3, 5-dihydro-pyrrolo [3, 2-D] pyrimidin-4-one | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130172368-A1 | Methods for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halogenic Acid and A Second Urate-Lowering Agent | METABOLEX, INC. | 2013-07-04 | — | — | US | disclosed |
| WO-2013066349-A1 | METHODS FOR TREATING HYPERURICEMIA IN PATIENTS WITH GOUT USING HALOFENATE OR HALOFENIC ACID AND A SECOND URATE-LOWERING AGENT | METABOLEX, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2012122532-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERURICEMIA | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| EP-2411394-A4 | USEFUL PHARMACEUTICAL SALTS OF 7-[(3R, 4R)-3-HYDROXY-4-HYDROXYMETHYL-PYRROLIDIN-1-YLMETHYL]-3,5-DIHYDRO-PYRROLO[3,2-D]PYRIMIDIN-4-ONE | BIOCRYST PHARM INC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120165526-A1 | Useful Pharmaceutical Salts of 7- [(3R, 4R) - 3 - Hydroxy -4 - Hydroxymethyl - Pyrrolidin -1- Ylmethyl] -3, 5-Dihydro-Pyrrolo [3, 2-D] Pyrimidin -4-One | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2012-06-28 | — | — | US | disclosed |
| US-20120165526-A1 | Useful Pharmaceutical Salts of 7- [(3R, 4R) - 3 - Hydroxy -4 - Hydroxymethyl - Pyrrolidin -1- Ylmethyl] -3, 5-Dihydro-Pyrrolo [3, 2-D] Pyrimidin -4-One | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2012-06-28 | — | — | US | disclosed |
| US-20120165526-A1 | Useful Pharmaceutical Salts of 7- [(3R, 4R) - 3 - Hydroxy -4 - Hydroxymethyl - Pyrrolidin -1- Ylmethyl] -3, 5-Dihydro-Pyrrolo [3, 2-D] Pyrimidin -4-One | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2012-06-28 | — | — | US | disclosed |
| CN-102448963-A | Useful pharmaceutical salts of 7- [ (3R,4R) -3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl ] -3, 5-dihydro-pyrrolo [3,2-d ] pyrimidin-4-one | BIOCRYST PHARM INC | 2012-05-09 | — | — | CN | disclosed |
| WO-2012050589-A1 | METHODS FOR TREATING HYPERURICEMIA AND RELATED DISEASES | ARDEA BIOSCIENCES, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
| EP-2411394-A2 | USEFUL PHARMACEUTICAL SALTS OF 7-[(3R, 4R)-3-HYDROXY-4-HYDROXYMETHYL-PYRROLIDIN-1-YLMETHYL]-3,5-DIHYDRO-PYRROLO[3,2-D]PYRIMIDIN-4-ONE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-02-01 | — | — | EP | disclosed |
| EP-2411394-A2 | USEFUL PHARMACEUTICAL SALTS OF 7-[(3R, 4R)-3-HYDROXY-4-HYDROXYMETHYL-PYRROLIDIN-1-YLMETHYL]-3,5-DIHYDRO-PYRROLO[3,2-D]PYRIMIDIN-4-ONE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-02-01 | — | — | EP | disclosed |
| EP-2411394-A2 | USEFUL PHARMACEUTICAL SALTS OF 7-[(3R, 4R)-3-HYDROXY-4-HYDROXYMETHYL-PYRROLIDIN-1-YLMETHYL]-3,5-DIHYDRO-PYRROLO[3,2-D]PYRIMIDIN-4-ONE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010111381-A3 | USEFUL PHARMACEUTICAL SALTS OF 7-[(3R, 4R)-3-HYDROXY-4-HYDROXYMETHYL-PYRROLIDIN-1-YLMETHYL]-3,5-DIHYDRO-PYRROLO[3,2-D]PYRIMIDIN-4-ONE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2010111381-A3 | USEFUL PHARMACEUTICAL SALTS OF 7-[(3R, 4R)-3-HYDROXY-4-HYDROXYMETHYL-PYRROLIDIN-1-YLMETHYL]-3,5-DIHYDRO-PYRROLO[3,2-D]PYRIMIDIN-4-ONE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2010111381-A2 | USEFUL PHARMACEUTICAL SALTS OF 7-[(3R, 4R)-3-HYDROXY-4-HYDROXYMETHYL-PYRROLIDIN-1-YLMETHYL]-3,5-DIHYDRO-PYRROLO[3,2-D]PYRIMIDIN-4-ONE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010111381-A2 | USEFUL PHARMACEUTICAL SALTS OF 7-[(3R, 4R)-3-HYDROXY-4-HYDROXYMETHYL-PYRROLIDIN-1-YLMETHYL]-3,5-DIHYDRO-PYRROLO[3,2-D]PYRIMIDIN-4-ONE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010111381-A2 | USEFUL PHARMACEUTICAL SALTS OF 7-[(3R, 4R)-3-HYDROXY-4-HYDROXYMETHYL-PYRROLIDIN-1-YLMETHYL]-3,5-DIHYDRO-PYRROLO[3,2-D]PYRIMIDIN-4-ONE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010111381-A2 | USEFUL PHARMACEUTICAL SALTS OF 7-[(3R, 4R)-3-HYDROXY-4-HYDROXYMETHYL-PYRROLIDIN-1-YLMETHYL]-3,5-DIHYDRO-PYRROLO[3,2-D]PYRIMIDIN-4-ONE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010111381-A2 | USEFUL PHARMACEUTICAL SALTS OF 7-[(3R, 4R)-3-HYDROXY-4-HYDROXYMETHYL-PYRROLIDIN-1-YLMETHYL]-3,5-DIHYDRO-PYRROLO[3,2-D]PYRIMIDIN-4-ONE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (37 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378482-A1 | Compositions and methods for potentiating immune response for the treatment of infectious diseases and cancer | PNP, PNLIP, RNASE1 | PNP 1/4885 |
| US-20140128439-A1 | Methods for Treating Gout Flares | SLC10A1, LIPA, NUDT1 | PNP 47/4885 |
| US-12006329-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | PNP 2238/4885 |
| US-20170209447-A1 | Use of PNP Inhibitor to Treat Relapse of Malignancy after Hematopoietic Stem Cell Transplant | PNP, NTPCR, PNLIP | PNP 1/4885 |
| US-20220354860-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | NUDT1, UGP2, NUDT21 | PNP 63/4885 |
| US-20230011269-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A POTENT INHIBITOR OF URAT1 | UGP2, MPST, SLC10A1 | PNP 112/4885 |
| US-20140377250-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE RESPONSE, ENHANCING IMMUNOTHERAPY, AND INCREASING VACCINE POTENCY | PNP, PNPLA2, PNLIP | PNP 1/4885 |
| US-10137112-B2 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | NUDT1, HACL2, XDH | PNP 24/4885 |
| US-20150258053-A1 | Methods for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halofenic Acid and a Second Urate-Lowering Agent | NUDT1, HACL2, XDH | PNP 24/4885 |
| US-20120165526-A1 | Useful Pharmaceutical Salts of 7- [(3R, 4R) - 3 - Hydroxy -4 - Hydroxymethyl - Pyrrolidin -1- Ylmethyl] -3, 5-Dihydro-Pyrrolo [3, 2-D] Pyrimidin -4-One | HPD, PGD, DPYD | PNP 1407/4885 |
| US-20160051520-A1 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | NUDT1, HACL2, XDH | PNP 24/4885 |
| US-20130274331-A1 | Method for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halofenic Acid and an Anti-Inflammatory Agent | NUDT1, LIPA, HACL2 | PNP 73/4885 |
| US-20230089949-A1 | SMALL MOLECULES FOR TREATING AGE-RELATED RETINAL DISEASES | PNP, PDE6B, PDE6A | PNP 1/4885 |
| US-20130296345-A1 | METHODS FOR TREATING HYPERURICEMIA AND RELATED DISEASES | XDH, PCSK9, PON1 | PNP 91/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | PNP 3454/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | PNP 2238/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | PNP 1485/4885 |
| US-20180161314-A1 | Methods for Treating Hyperuricemia and Related Diseases | XDH, PCSK9, PON1 | PNP 91/4885 |
| US-20260000663-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | RBP4, RBP1, FABP1 | PNP 489/4885 |
| US-12440486-B2 | RBP4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout | RBP4, RBP1, FABP1 | PNP 845/4885 |
| US-20250127787-A1 | METHODS FOR TREATING PERIPHERAL NEUROPATHY | PNP, PNPO, PRPH | PNP 1/4885 |
| US-20220305129-A1 | CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | NQO1, ABCB1, NCL | PNP 516/4885 |
| US-20180055803-A1 | Methods for Treating Gout Flares | SLC10A1, LIPA, NUDT1 | PNP 47/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | PNP 913/4885 |
| US-20180214420-A1 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | NUDT1, HACL2, XDH | PNP 24/4885 |
| US-11623932-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | PNP 2238/4885 |
| US-20230241049-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | RBP4, RBP1, FABP1 | PNP 845/4885 |
| US-20130302305-A1 | Methods for Treating Gout in Patients Subpopulations | OAT, SLC10A1, XDH | PNP 56/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | PNP 2238/4885 |
| US-20220054494-A1 | METHODS FOR TREATING BLADDER AND URETHRA DYSFUNCTION AND DISEASE | PNP, UNG, PDE3A | PNP 1/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | PNP 698/4885 |
| US-20130172368-A1 | Methods for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halogenic Acid and A Second Urate-Lowering Agent | PON1, XDH, LIPA | PNP 30/4885 |
| US-20230065814-A1 | CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | NQO1, NCL, ABCB1 | PNP 759/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | PNP 1485/4885 |
| US-20140128438-A1 | Methods for Treating Gout Flares | SLC10A1, LIPA, NUDT1 | PNP 47/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | PNP 913/4885 |
| US-20160271111-A1 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | NUDT1, HACL2, XDH | PNP 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.